1. Healthcare

  2. •

    Medical - Pharmaceuticals
Shire plc

Shire plc

SHPG
Shire plcUS flagNASDAQ
179.20
USD
- -
- -
Shire plc
SHPG
(NASDAQ)

Recent

price

179.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
TTM
FRC
6.22
7.45
8.24
9.59
10.71
13.53
16.74
16.69
19.06
23.21
25.29
26.82
30.79
32.61
44.4
50.17
51.7
Revenue per Share
1.5
1.66
1.63
-2.46
1.66
-8.06
0.86
2.73
3.23
4.71
4.03
3.61
17.41
6.62
1.28
14.14
15.83
Basic EPS, GAAP
1.86
1.83
2.54
1.77
2.22
1.7
2.99
2.03
3.44
4.76
6.43
7.1
21.23
11.29
7.83
11.44
11.62
Free Cash Flow per Basic Share
- -
- -
0.05
0.17
0.19
0.23
0.26
0.3
0.34
0.4
0.47
0.52
0.62
0.68
0.67
0.93
1.06
Dividend per Share
1.88
3.55
5.14
2.48
2.36
-6.06
-5.52
-3.14
-0.57
3.04
5.68
8.26
24.04
29.71
23.4
33.1
37.98
Book Value per Share
6.4
7.22
10.31
4.15
5.62
-4.2
-4.86
-1.46
0.38
0.54
4.19
13.2
6.41
-17.74
-92.08
-55.27
-37.64
Tangible Book Value per Share
167
166
165
167
168
180
181
180
182
184
185
184
196
197
257
302
304
Basic Weighted Avg Shares
1,037
1,237
1,363
1,599
1,796
2,436
3,022
3,008
3,471
4,263
4,681
4,934
6,022
6,417
11,397
15,161
15,702
Sales/Revenue/Turnover
31.53
31.9
32.75
-21.56
16.08
20.06
22.34
21.4
24.1
27.05
20.43
34.43
35.53
34.07
17.13
22.41
25.89
Operating Margin (%)
36
42
61
72
104
172
203
250
256
295
309
152
407
637
1,466
1,768
2,296
Depreciation Expense
251
276
269
-411
278
-1,452
156
492
588
865
745
665
3,406
1,303
327
4,272
4,809
Net Income, GAAP
26.71
28
27.92
- -
26.8
- -
36.9
21.54
23.75
20.88
18.32
16.41
1.68
3.33
- -
- -
51.87
Effective Tax Rate (%)
24.16
22.31
19.73
-25.69
15.49
-59.59
5.16
16.34
16.94
20.29
15.92
13.48
56.55
20.31
2.87
28.18
30.63
Profit Margin (%)
1,254
1,534
1,497
347
478
435
221
550
587
-326
1,566
2,480
2,161
-1,451
-204
-274
-712
Working Capital
407
377
- -
- -
- -
1,133
1,143
1,144
1,108
- -
1,100
- -
- -
70
19,900
16,752
11,098
LT Debt
1,573
1,923
2,251
1,789
1,942
1,227
1,298
1,912
2,451
3,185
3,809
5,366
8,663
9,829
28,948
36,176
37,290
Total Equity
13.13
13.24
13.83
- -
10.25
- -
17.41
18.17
19.15
23.22
16.88
27.38
28.24
20.18
- -
- -
- -
Return on Invested Capital (%)
41.99
30.07
27.1
- -
73.14
- -
262.12
144.48
77.81
67.32
40.77
37.97
97.16
20.7
- -
- -
51.62
Return on Capital (%)
132.44
61.03
37.34
-64.96
68.62
- -
- -
- -
- -
- -
92.61
51.73
109.46
24.71
5.52
53.36
52.04
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
ST Debt
1,787
1,193
4,249
LT Borrowings
16,392
16,383
10,741
LT Finance Leases
342
339
357
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
911
913
915
Market Capitalization
45,162
51,117
55,050

Working Capital

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
Total Current Assets
7,915
9,788
7,799
Cash, Cash Equivalents & STI
318
260
193
Accounts Receivable, Net
3,140
3,005
3,207
Inventories
3,341
3,353
3,459
Total Current Liabilities
6,945
6,307
8,512
Payables & Accruals
- -
- -
- -
ST Debt
1,787
1,193
4,249
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.61%
67.05%
24.97%
Free Cash Flow
43.5%
48.73%
72.02%
Net Income, GAAP
162.66%
293.86%
1,204.67%
Sales/Revenue/Turnover
21.63%
28.93%
33.03%
Total Cash Common Dividend
21.95%
28%
64.21%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
1,709
2,429
3,452
3,806
11,397
2017
3,572
3,746
3,698
4,145
15,161
2018
3,766
3,920
3,872
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
2.12
-0.71
-1.29
1.52
1.28
2017
1.24
0.8
1.82
10.26
14.14
2018
1.82
2.02
1.76
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
0.57
- -
0.14
0.67
2017
- -
0.78
- -
0.15
0.93
2018
- -
0.91
- -
- -
- -
Similar Companies
Kimia Biosciences Ltd. (KIMIABL.BO)
Irwin Naturals Inc. (IWINF)
Neuphoria Therapeutics Inc. (NEUP)
Fredun Pharmaceuticals Limited (FREDUN.BO)
MatsukiyoCocokara & Co. (3088.T)
Progressive Care, Inc. (RXMD)
Business
Shire plc was formerly a prominent specialty biopharmaceutical company, originally founded in the United Kingdom with operational hubs in the United States and Ireland. It focused on the research, development, manufacturing, and commercialization of treatments for rare diseases and other highly specialized medical conditions across more than 100 countries. The company's diverse product portfolio addressed critical therapeutic areas, including hematology, immunology, neuroscience, genetic diseases, and gastrointestinal disorders. Key medicines included treatments for conditions such as attention-deficit/hyperactivity disorder (ADHD), hemophilia, lysosomal storage disorders, and hereditary angioedema. Shire expanded significantly through strategic acquisitions, notably the $32 billion purchase of Baxalta in 2016, which solidified its position as a major player in the rare disease biotechnology sector. Shire plc was acquired by Takeda Pharmaceutical Company Limited in a $62 billion transaction that concluded on January 8, 2019. Following this acquisition, Shire ceased to operate as an independent entity, and its extensive pipeline and specialized products were integrated into Takeda's global biopharmaceutical operations.

Company News

APIChat

  • accessnewswire.com

    Sun Peak Provides an Update on the Shire Project

  • accessnewswire.com

    Sun Peak Provides an Update on the Shire Project

  • accesswire.com

    Sun Peak Metals to Continue Next Phase of Work on the Shire Copper-Gold VMS Project

  • prismmediawire.com

    Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

  • globenewswire.com

    Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

  • businesswire.com

    Tales of the Shire: A The Lord of The Rings Game Launches on March 25, 2025

  • globenewswire.com

    Structure Therapeutics Appoints Angus C. Russell to Board of Directors

  • accesswire.com

    Sun Peak Metals Completes Initial 2024 Drill Program at the Shire Project

  • investorplace.com

    Why I Just Made That Big Reversal on Income Investing